84-1040-36　β-Amyloid 1-40, 42 100ul　A2275-74M

特徴

• Alzheimer's Disease (AD) is a neurodegenerative disorder characterized by progressive loss of memory and cognition in the elderly.
• One of the most important and initial step involves proteolytic cleavage of amyloid precursor protein (APP, chromosome 21) releasing short 40, 42 & 43 aa peptides (beta amyloid1-40, 1-42, and 1-43).
• Polymerization of b-amyloid (Ab) and subsequent neuronal deposit (amyloid) leads to the degeneration of neurons involved in memory and cognition.
• Ab deposits have also been found to contain 2 additional proteins termed a-synuclein and b-synuclein.
• The 140 aa a-synucleins is identical with non- Ab component (NACP) of AD.
• The 134 aa human b-synuclein is homologous to 14kD bovine phosphoneuroprotein 14.
• Mutations in a-synuclein gene causing a replacement of alanine with a threonine may cause the protein to misfold.
• Synucleins are primarily expressed in the brain.
• At least 3 forms: two large (140 aa SYN-1 & 149 aa SYN-2) and a small form (SYN-3, 42 aa) are produced by alternative splicing.
• Rabbit anti-human beta Amyloid antibodies was raised using synthetic b-amyloid conjugated to BSA.
• Full-length b-amyloid 1-40 control immunogenic peptide is also available to confirm specificity of antibodies (A2275-75G).
• Applications:Suitable for use in ELISA.
• Western Blot, though not tested, may potentially be used as an application.
• Other applications not tested.
• Recommended Dilution:Western Blot: 1:1000-1:5000ELISA: 1:10,000-1:100,000 using 50-100ng of control peptide/well
• Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only.
• For long-term storage, store at -20°C.
• Aliquots are stable for at least 12 months at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.